Buy & Sell Danaher Corporation (DHR) – Danaher Corporation Price Today
Aura AI Summary
Key Stats
- $124.33BMarket Cap
- HealthSector
- -20.88%3M Drawdown
- $137.11BEnterprise Value
- 0.91%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 70 daysTypical Hold Time
Danaher Corporation (DHR) is currently valued at a market capitalization of $124.33B, with an enterprise value of $137.11B. Over the past 52 weeks, Danaher Corporation has traded between a low of $174.04 and a high of $242.05, highlighting its annual price range. Over the past three months, Danaher Corporation has recorded a drawdown of -20.88%, reflecting recent price volatility. Danaher Corporation offers a dividend yield of 0.91%, with the most recent dividend of $0.40 paid on 27 Mar 26. On average, investors hold Danaher Corporation for approximately 70 days, indicating typical investor behavior on the platform.
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Most Recent News
Wrap Technologies to showcase non-lethal BolaWrap system at European law enforcement event in Italy
Wrap Technologies will present its non-lethal BolaWrap device, immersive WrapReality training, and policy strategies at a European law enforcement conference in Italy on May 13-14, 2026. The event aims to introduce safer, modern public safety tools t...
FDA agrees on two clearance pathways for BioCardia's Helix delivery catheter, favoring simultaneous CardiAMP therapy approval.
BioCardia announced that the FDA agreed on two possible marketing clearance pathways for its Helix Transendocardial Delivery Catheter System, with no safety or performance concerns raised. The FDA's preferred approval route is simultaneous with the C...
US Treasury may borrow over $2 trillion in fiscal 2026 amid rising debt and costs.
The US Treasury plans to borrow more than $2 trillion from private markets in fiscal year 2026, driven by a projected $2.065 trillion deficit and rising national debt nearing $39 trillion. Borrowing needs are expected to stay above $2 trillion throug...
